CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer.

Xiaoxia Wei; Jiaqin Cai; J. Zhuang; Bin Zheng; Yuxia Sui; Guifeng Zhang; Y. Lin; H. Sun

DOI:10.2217/pgs-2019-0073

Corpus ID: 208299469

CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer.

@article{Wei2019CYP2D610PS,
  title={CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer.},
  author={Xiaoxia Wei and Jiaqin Cai and J. Zhuang and Bin Zheng and Yuxia Sui and Guifeng Zhang and Y. Lin and H. Sun},
  journal={Pharmacogenomics},
  year={2019}
}

Xiaoxia Wei, Jiaqin Cai, +5 authors H. Sun

Published 2019

Medicine

Pharmacogenomics

Aim: To assess the cost-effectiveness of CYP2D6*10 genetic testing for the management of Chinese women with hormone receptor-positive (HR+) breast cancer treated with selective estrogen receptor modulator. Methods: A Markov model was developed to evaluate a total expected cost and an incremental cost-effectiveness ratio (ICER). Robustness of the model was addressed in one-way analyses and probabilistic sensitivity analysis. Results: The cost of strategies of tamoxifen, toremifene without… CONTINUE READING

View on PubMed

Share This Paper

1 Citations

Topics from this paper

Explore Further: Topics Discussed in This Paper

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen

C. Chan, Bernard M. H. Law, W. So, K. M. Chow, M. M. Waye
Medicine
Journal of Cancer Research and Clinical Oncology
2020

References

SHOWING 1-10 OF 22 REFERENCES

SORT BY

Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.

Beth S Woods, D. Veenstra, N. Hawkins
Medicine
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
2011